[
  {
    "ts": null,
    "headline": "Earnings Season Highlights on Tariffs, Consumer Spending, and More",
    "summary": "Back-to-school spending is strong, and other revelations from RBC’s reading of S&P 500 earnings-call transcripts. Plus, investment newsletter commentary on interest rates, agriculture, and healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=1eee0be7daf01f77c3f589d2670989398e38cef7a9ac1a1b65c3395f32c61c7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756499040,
      "headline": "Earnings Season Highlights on Tariffs, Consumer Spending, and More",
      "id": 136579597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Back-to-school spending is strong, and other revelations from RBC’s reading of S&P 500 earnings-call transcripts. Plus, investment newsletter commentary on interest rates, agriculture, and healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=1eee0be7daf01f77c3f589d2670989398e38cef7a9ac1a1b65c3395f32c61c7b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Ends RA Combo After Mid-Stage Miss",
    "summary": "Therapy showed no extra benefit over Humira but pipeline stays alive",
    "url": "https://finnhub.io/api/news?id=73ef693a87b65ef49a1d538dc14111bbbe1c9ee33b451b99e8d02c02220a57cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756494730,
      "headline": "Johnson & Johnson Ends RA Combo After Mid-Stage Miss",
      "id": 136575319,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Therapy showed no extra benefit over Humira but pipeline stays alive",
      "url": "https://finnhub.io/api/news?id=73ef693a87b65ef49a1d538dc14111bbbe1c9ee33b451b99e8d02c02220a57cf"
    }
  },
  {
    "ts": null,
    "headline": "J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure",
    "summary": "JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.",
    "url": "https://finnhub.io/api/news?id=8902375208a92aa1b0b782f4280593cf50374f96a7ad844705c65b5869c790f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756480380,
      "headline": "J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure",
      "id": 136573043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.",
      "url": "https://finnhub.io/api/news?id=8902375208a92aa1b0b782f4280593cf50374f96a7ad844705c65b5869c790f8"
    }
  },
  {
    "ts": null,
    "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
    "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
    "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756477020,
      "headline": "ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?",
      "id": 136573040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.",
      "url": "https://finnhub.io/api/news?id=5778f05411a82196571c26c33b1c12ac8249bff2e5939836b87b49deb3fee059"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=8419144d13de43090f0e3e703ebc571e6995e6ab4de2e3660a75f823e2c5a7cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756472405,
      "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136569071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=8419144d13de43090f0e3e703ebc571e6995e6ab4de2e3660a75f823e2c5a7cb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
    "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
    "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756471054,
      "headline": "AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin",
      "id": 136571810,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and Skyrizi. Click here to read my latest analysis.",
      "url": "https://finnhub.io/api/news?id=cd5b0e7f7073f7c6b99befc729473d98b794028f55711773ec7140c00fc76cbf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's Biosense Webster Unit Hit With Injunction for Antitrust Violations",
    "summary": "Johnson & Johnson's (JNJ) Biosense Webster medical device unit has been hit with a permanent injunct",
    "url": "https://finnhub.io/api/news?id=7bd2b68777fedd9aed86d6cb22e0d98a4e15aef8c19ce34f7dad8143711b3477",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756469062,
      "headline": "Johnson & Johnson's Biosense Webster Unit Hit With Injunction for Antitrust Violations",
      "id": 136569072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson's (JNJ) Biosense Webster medical device unit has been hit with a permanent injunct",
      "url": "https://finnhub.io/api/news?id=7bd2b68777fedd9aed86d6cb22e0d98a4e15aef8c19ce34f7dad8143711b3477"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program",
    "summary": "Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease. Rheumatoid arthritis (RA) is a long-term autoimmune disorder causing inflammation, pain, and swelling in joints, typically the hands and wrists, and often on both sides of the body. In 2020, Johnson & Johnson shelled out $6.5",
    "url": "https://finnhub.io/api/news?id=896491809f8739bbed803554c4bc81d8df1300f48e9d8445d47d205a7070bf13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756466508,
      "headline": "Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program",
      "id": 136569073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease. Rheumatoid arthritis (RA) is a long-term autoimmune disorder causing inflammation, pain, and swelling in joints, typically the hands and wrists, and often on both sides of the body. In 2020, Johnson & Johnson shelled out $6.5",
      "url": "https://finnhub.io/api/news?id=896491809f8739bbed803554c4bc81d8df1300f48e9d8445d47d205a7070bf13"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?",
    "summary": "Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.",
    "url": "https://finnhub.io/api/news?id=db00b9a34b92efcdbc388ef337b285a52e35f0c8683c500224d103081180a6d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756465866,
      "headline": "Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector?",
      "id": 136569045,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Although Eli Lilly has trailed the broader healthcare sector over the past year, analysts maintain a strongly bullish outlook on the stock’s long-term growth potential.",
      "url": "https://finnhub.io/api/news?id=db00b9a34b92efcdbc388ef337b285a52e35f0c8683c500224d103081180a6d3"
    }
  },
  {
    "ts": null,
    "headline": "Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma and epcoritamab for B-cell malignancies. Strategic partnerships with AbbVie and […]",
    "url": "https://finnhub.io/api/news?id=18b64cb23bd65c41a7e535bb5e783d419dd3b287701aca0739e25105a0446f37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756458757,
      "headline": "Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma",
      "id": 136569075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma and epcoritamab for B-cell malignancies. Strategic partnerships with AbbVie and […]",
      "url": "https://finnhub.io/api/news?id=18b64cb23bd65c41a7e535bb5e783d419dd3b287701aca0739e25105a0446f37"
    }
  },
  {
    "ts": null,
    "headline": "How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?",
    "summary": "Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=cd43cd3c26f293a345b94c79c92dd22a8b69e7a35a0c94307e458548ba121bc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756450402,
      "headline": "How Is Johnson & Johnson’s Stock Performance Compared to Other Healthcare Stocks?",
      "id": 136569076,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has significantly outperformed other healthcare stocks over the past year, and analysts remain moderately bullish on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=cd43cd3c26f293a345b94c79c92dd22a8b69e7a35a0c94307e458548ba121bc5"
    }
  }
]